share_log

Shareholders 8.6% Loss in Gilead Sciences (NASDAQ:GILD) Partly Attributable to the Company's Decline in Earnings Over Past Year

Shareholders 8.6% Loss in Gilead Sciences (NASDAQ:GILD) Partly Attributable to the Company's Decline in Earnings Over Past Year

吉利德科學(納斯達克股票代碼:GILD)過去一年收益下降,致股東損失8.6%
Simply Wall St ·  06/22 02:53

The simplest way to benefit from a rising market is to buy an index fund. While individual stocks can be big winners, plenty more fail to generate satisfactory returns. That downside risk was realized by Gilead Sciences, Inc. (NASDAQ:GILD) shareholders over the last year, as the share price declined 12%. That falls noticeably short of the market return of around 25%. On the other hand, the stock is actually up 2.0% over three years. On the other hand the share price has bounced 7.8% over the last week.

從指數基金入手是受益於上漲市場最簡單的方式。雖然個股可能有大贏家,但更多的個股無法帶來令人滿意的回報。吉利德科學股份有限公司(納斯達克股票代碼:GILD)股價下跌了12%,這種下行風險在過去一年中已經得到了體現。相比之下,市場回報率約爲25%,明顯低於市場回報率的表現。另一方面,股票實際上上漲了2.0%,而股價在過去一週內反彈了7.8%。上漲6.3%的三年中,股票的價格似乎沒有反映出EPS的增長。所以,有理由對一些其他指標進行研究。三年內上漲了2.0%,然而,在過去一週,股價上漲了7.8%。

The recent uptick of 7.8% could be a positive sign of things to come, so let's take a look at historical fundamentals.

股價最近上漲了7.8%,這可能是一件好事,所以讓我們來看看歷史基本面的情況。

While the efficient markets hypothesis continues to be taught by some, it has been proven that markets are over-reactive dynamic systems, and investors are not always rational. One imperfect but simple way to consider how the market perception of a company has shifted is to compare the change in the earnings per share (EPS) with the share price movement.

雖然一些人仍然相信有效市場假說,但已經證明市場是過度反應的動態系統,投資者並不總是理性的。一個不完美但簡單的方法來考慮公司市場看法的變化是比較每股收益(EPS)的變化和股價的波動。

Unhappily, Gilead Sciences had to report a 91% decline in EPS over the last year. This fall in the EPS is significantly worse than the 12% the share price fall. So the market may not be too worried about the EPS figure, at the moment -- or it may have expected earnings to drop faster. With a P/E ratio of 175.94, it's fair to say the market sees an EPS rebound on the cards.

不幸的是,吉利德科學過去一年的每股收益率下降了91%。收益率下降的幅度遠大於股價下跌的12%,市場可能暫時不會太關注EPS數據,或者可能已經預期收益下降得更快了。以175.94的市盈率來看,市場認爲EPS將會出現反彈。

You can see below how EPS has changed over time (discover the exact values by clicking on the image).

下面可以看到每股收益隨時間的變化情況(通過點擊圖像來查看確切數值)。

earnings-per-share-growth
NasdaqGS:GILD Earnings Per Share Growth June 21st 2024
納斯達克股票代碼:GILD,截至2024年6月21日的每股收益增長

Dive deeper into Gilead Sciences' key metrics by checking this interactive graph of Gilead Sciences's earnings, revenue and cash flow.

通過檢查吉利德科學的收益、營業收入和現金流的交互式圖表,更深入地了解吉利德科學的關鍵指標。

What About Dividends?

那麼分紅怎麼樣呢?

When looking at investment returns, it is important to consider the difference between total shareholder return (TSR) and share price return. The TSR incorporates the value of any spin-offs or discounted capital raisings, along with any dividends, based on the assumption that the dividends are reinvested. It's fair to say that the TSR gives a more complete picture for stocks that pay a dividend. As it happens, Gilead Sciences' TSR for the last 1 year was -8.6%, which exceeds the share price return mentioned earlier. The dividends paid by the company have thusly boosted the total shareholder return.

在考慮投資回報時,重要的是考慮總股東回報(TSR)和股票回報之間的差異。 TSR包括任何剝離或折讓的資本籌集(基於股息被重新投資的假設),以及任何股息。因此,對於支付慷慨的股息公司而言,TSR通常比股票回報高得多。就中國神威藥業集團而言,其TSR在過去5年中達到了75%。這超過了我們之前提到的股票回報。該公司支付的股息已經提高了總股東回報。總股東回報股票回報TSR統計了任何分離或優惠的融資的價值,以及任何股息,並基於股息再投資的假設,可以說TSR爲支付股息的股票提供了更完整的情況。現實情況是,吉利德科學過去一年的TSR爲-8.6%,超過了前面提到的股價回報。公司支付的股息因此提高了回報率。吉利德科學的股東經歷了艱難的一年,股價總損失達8.6%(包括股息),而市場盈利約爲25%。然而,即使是最好的股票有時也會在12個月的時間內跑輸市場。長期投資者不會感到那麼苦惱,因爲他們在過去的五年中每年都獲得了5%的回報。如果基本數據繼續表明長期可持續的增長,那麼當前的拋售可能值得考慮。雖然考慮市場對股價的不同影響的不同,但有其他更重要的因素。請考慮風險。每家公司都有風險,我們已經發現了吉利德科學的4個警示信號,您應該了解。股東回報。

A Different Perspective

不同的觀點

Investors in Gilead Sciences had a tough year, with a total loss of 8.6% (including dividends), against a market gain of about 25%. However, keep in mind that even the best stocks will sometimes underperform the market over a twelve month period. Longer term investors wouldn't be so upset, since they would have made 5%, each year, over five years. If the fundamental data continues to indicate long term sustainable growth, the current sell-off could be an opportunity worth considering. While it is well worth considering the different impacts that market conditions can have on the share price, there are other factors that are even more important. Consider risks, for instance. Every company has them, and we've spotted 4 warning signs for Gilead Sciences you should know about.

吉利德科學的股東經歷了艱難的一年,股價總損失達8.6%(包括股息),而市場盈利約爲25%。然而,即使是最好的股票有時也會在12個月的時間內跑輸市場。長期投資者不會感到那麼苦惱,因爲他們在過去的五年中每年都獲得了5%的回報。如果基本數據繼續表明長期可持續的增長,那麼當前的拋售可能值得考慮。雖然考慮市場對股價的不同影響的不同,但有其他更重要的因素。請考慮風險。每家公司都有風險,我們已經發現了吉利德科學的4個警示信號,您應該了解。

Of course, you might find a fantastic investment by looking elsewhere. So take a peek at this free list of companies we expect will grow earnings.

當然,您可能在其他地方找到一家出色的企業進行投資。因此,請查看我們預計將實現盈利增長的公司的免費列表。

Please note, the market returns quoted in this article reflect the market weighted average returns of stocks that currently trade on American exchanges.

請注意,本文所引述的市場回報反映了目前在美國交易所上市的股票的市場加權平均回報。

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

對本文有反饋?關於內容有所顧慮?直接和我們聯繫。或者,發送電子郵件至editorial-team (at) simplywallst.com。
這篇文章是Simply Wall St的一般性文章。我們根據歷史數據和分析師預測提供評論,只使用公正的方法論,我們的文章並不意味着提供任何金融建議。文章不構成買賣任何股票的建議,也不考慮您的目標或您的財務狀況。我們的目標是帶給您基本數據驅動的長期關注分析。請注意,我們的分析可能不考慮最新的價格敏感公司公告或定性材料。Simply Wall St沒有任何股票頭寸。

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com

對本文有反饋?關於內容有所顧慮?直接和我們聯繫。或者發送電子郵件至editorial-team@simplywallst.com。

譯文內容由第三人軟體翻譯。


以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
    搶先評論